ATAI - Company ID 0001840904
The table below shows ATAI Life Sciences N.V.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$17.84M | -$22.57M | -$21.11M | -$23.99M | -$16.52M |
| Capital expenditure | $268.00K | $0.00 | $280.00K | $56.00K | $175.00K |
| Investing cash flow | -$11.01M | $11.47M | $16.02M | -$214.74M | -$3.72M |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - |
ATAI Life Sciences N.V. reported operating cash flow of -$82.44M for fiscal year 2024. That is up 2.0% from -$84.12M in fiscal 2023. Over the 5 fiscal years shown, operating cash flow declined from -$20.77M (FY 2020) to -$82.44M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| $1.00M |
| $1.00M |
| - |
| Financing cash flow | $59.60M | $0.00 | $206.00K | $132.00K | $30.50M |